ID   CARL2_HUMAN             Reviewed;        1435 AA.
AC   Q6F5E8; B8X2Z3;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   18-MAR-2008, sequence version 2.
DT   28-JUN-2023, entry version 135.
DE   RecName: Full=Capping protein, Arp2/3 and myosin-I linker protein 2 {ECO:0000303|PubMed:19846667};
DE   AltName: Full=Capping protein regulator and myosin 1 linker 2 {ECO:0000312|HGNC:HGNC:27089};
DE   AltName: Full=F-actin-uncapping protein RLTPR {ECO:0000305};
DE   AltName: Full=Leucine-rich repeat-containing protein 16C;
DE   AltName: Full=RGD, leucine-rich repeat, tropomodulin and proline-rich-containing protein {ECO:0000303|PubMed:15588584};
GN   Name=CARMIL2 {ECO:0000312|HGNC:HGNC:27089};
GN   Synonyms=LRRC16C, RLTPR {ECO:0000303|PubMed:15588584};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, TISSUE
RP   SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   TISSUE=Keratinocyte;
RX   PubMed=15588584; DOI=10.1016/j.gene.2004.09.004;
RA   Matsuzaka Y., Okamoto K., Mabuchi T., Iizuka M., Ozawa A., Oka A.,
RA   Tamiya G., Kulski J.K., Inoko H.;
RT   "Identification, expression analysis and polymorphism of a novel RLTPR gene
RT   encoding a RGD motif, tropomodulin domain and proline/leucine-rich
RT   regions.";
RL   Gene 343:291-304(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND SUBCELLULAR LOCATION
RP   (ISOFORM 2).
RX   PubMed=19846667; DOI=10.1091/mbc.e08-10-1071;
RA   Liang Y., Niederstrasser H., Edwards M., Jackson C.E., Cooper J.A.;
RT   "Distinct roles for CARMIL isoforms in cell migration.";
RL   Mol. Biol. Cell 20:5290-5305(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-993 AND SER-1246, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   FUNCTION, INTERACTION WITH F-ACTIN-CAPPING PROTEIN (ISOFORM 2), SUBCELLULAR
RP   LOCATION (ISOFORM 2), DOMAIN (ISOFORM 2), AND MUTAGENESIS OF ARG-1021 AND
RP   ARG-1023.
RX   PubMed=26466680; DOI=10.1091/mbc.e15-08-0552;
RA   Lanier M.H., Kim T., Cooper J.A.;
RT   "CARMIL2 is a novel molecular connection between vimentin and actin
RT   essential for cell migration and invadopodia formation.";
RL   Mol. Biol. Cell 26:4577-4588(2015).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION (ISOFORM 2), DOMAIN (ISOFORM 2), AND
RP   MUTAGENESIS OF 1096-LYS--LYS-1106.
RX   PubMed=26578515; DOI=10.1074/jbc.m115.676882;
RA   Lanier M.H., McConnell P., Cooper J.A.;
RT   "Cell migration and invadopodia formation require a membrane-binding domain
RT   of CARMIL2.";
RL   J. Biol. Chem. 291:1076-1091(2016).
RN   [12]
RP   FUNCTION, SUBUNIT, TISSUE SPECIFICITY, INVOLVEMENT IN IMD58, VARIANTS IMD58
RP   ARG-372; GLN-525 AND 853-GLN--PRO-1435 DEL, AND CHARACTERIZATION OF
RP   VARIANTS IMD58 ARG-372; GLN-525 AND 853-GLN--PRO-1435 DEL.
RX   PubMed=27647349; DOI=10.1084/jem.20160576;
RA   Wang Y., Ma C.S., Ling Y., Bousfiha A., Camcioglu Y., Jacquot S., Payne K.,
RA   Crestani E., Roncagalli R., Belkadi A., Kerner G., Lorenzo L., Deswarte C.,
RA   Chrabieh M., Patin E., Vincent Q.B., Mueller-Fleckenstein I.,
RA   Fleckenstein B., Ailal F., Quintana-Murci L., Fraitag S., Alyanakian M.A.,
RA   Leruez-Ville M., Picard C., Puel A., Bustamante J., Boisson-Dupuis S.,
RA   Malissen M., Malissen B., Abel L., Hovnanian A., Notarangelo L.D.,
RA   Jouanguy E., Tangye S.G., Beziat V., Casanova J.L.;
RT   "Dual T cell- and B cell-intrinsic deficiency in humans with biallelic
RT   RLTPR mutations.";
RL   J. Exp. Med. 213:2413-2435(2016).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=27647348; DOI=10.1084/jem.20160579;
RA   Roncagalli R., Cucchetti M., Jarmuzynski N., Gregoire C., Bergot E.,
RA   Audebert S., Baudelet E., Menoita M.G., Joachim A., Durand S., Suchanek M.,
RA   Fiore F., Zhang L., Liang Y., Camoin L., Malissen M., Malissen B.;
RT   "The scaffolding function of the RLTPR protein explains its essential role
RT   for CD28 co-stimulation in mouse and human T cells.";
RL   J. Exp. Med. 213:2437-2457(2016).
RN   [14]
RP   INVOLVEMENT IN IMD58, AND VARIANT IMD58 HIS-639.
RX   PubMed=27896283; DOI=10.1002/mgg3.237;
RA   Sorte H.S., Osnes L.T., Fevang B., Aukrust P., Erichsen H.C., Backe P.H.,
RA   Abrahamsen T.G., Kittang O.B., Oeverland T., Jhangiani S.N., Muzny D.M.,
RA   Vigeland M.D., Samarakoon P., Gambin T., Akdemir Z.H., Gibbs R.A.,
RA   Roedningen O.K., Lyle R., Lupski J.R., Stray-Pedersen A.;
RT   "A potential founder variant in CARMIL2/RLTPR in three Norwegian families
RT   with warts, molluscum contagiosum, and T-cell dysfunction.";
RL   Mol. Genet. Genomic Med. 4:604-616(2016).
RN   [15]
RP   FUNCTION, AND INVOLVEMENT IN IMD58.
RX   PubMed=28112205; DOI=10.1038/ncomms14209;
RA   Schober T., Magg T., Laschinger M., Rohlfs M., Linhares N.D., Puchalka J.,
RA   Weisser T., Fehlner K., Mautner J., Walz C., Hussein K., Jaeger G.,
RA   Kammer B., Schmid I., Bahia M., Pena S.D., Behrends U., Belohradsky B.H.,
RA   Klein C., Hauck F.;
RT   "A human immunodeficiency syndrome caused by mutations in CARMIL2.";
RL   Nat. Commun. 8:14209-14209(2017).
RN   [16]
RP   VARIANT IMD58 THR-50, AND CHARACTERIZATION OF VARIANT IMD58 THR-50.
RX   PubMed=29479355; DOI=10.3389/fimmu.2018.00203;
RA   Alazami A.M., Al-Helale M., Alhissi S., Al-Saud B., Alajlan H., Monies D.,
RA   Shah Z., Abouelhoda M., Arnaout R., Al-Dhekri H., Al-Numair N.S.,
RA   Ghebeh H., Sheikh F., Al-Mousa H.;
RT   "Novel CARMIL2 mutations in patients with variable clinical dermatitis,
RT   infections, and combined immunodeficiency.";
RL   Front. Immunol. 9:203-203(2018).
CC   -!- FUNCTION: Cell membrane-cytoskeleton-associated protein that plays a
CC       role in the regulation of actin polymerization at the barbed end of
CC       actin filaments. Prevents F-actin heterodimeric capping protein (CP)
CC       activity at the leading edges of migrating cells, and hence generates
CC       uncapped barbed ends and enhances actin polymerization
CC       (PubMed:26466680). Plays a role in cell protrusion formations; involved
CC       in cell polarity, lamellipodial assembly, membrane ruffling and
CC       macropinosome formations (PubMed:19846667, PubMed:26578515,
CC       PubMed:26466680). Involved as well in cell migration and invadopodia
CC       formation during wound healing (PubMed:19846667, PubMed:26578515,
CC       PubMed:26466680). Required for CD28-mediated stimulation of NF-kappa-B
CC       signaling, involved in naive T cells activation, maturation into T
CC       memory cells, and differentiation into T helper and T regulatory cells
CC       (PubMed:27647349, PubMed:27647348, PubMed:28112205).
CC       {ECO:0000269|PubMed:19846667, ECO:0000269|PubMed:26466680,
CC       ECO:0000269|PubMed:26578515, ECO:0000269|PubMed:27647348,
CC       ECO:0000269|PubMed:27647349, ECO:0000269|PubMed:28112205}.
CC   -!- SUBUNIT: Forms homodimers (PubMed:27647349, PubMed:27647348). Interacts
CC       (via C-terminus) with heterodimeric capping protein (CP); the
CC       interaction inhibits CP activity and hence promotes actin
CC       polymerization at the barbed end of actin filaments (PubMed:26466680).
CC       {ECO:0000269|PubMed:26466680, ECO:0000269|PubMed:27647348,
CC       ECO:0000269|PubMed:27647349}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:19846667, ECO:0000269|PubMed:26466680}. Cytoplasm,
CC       cytoskeleton {ECO:0000269|PubMed:19846667, ECO:0000269|PubMed:26466680,
CC       ECO:0000269|PubMed:26578515}. Cell membrane
CC       {ECO:0000269|PubMed:26466680, ECO:0000269|PubMed:26578515}; Peripheral
CC       membrane protein {ECO:0000305}; Cytoplasmic side {ECO:0000305}. Cell
CC       projection, lamellipodium {ECO:0000269|PubMed:26578515}. Cell
CC       projection, ruffle {ECO:0000269|PubMed:26466680,
CC       ECO:0000269|PubMed:26578515}. Note=Colocalizes to dynamic vimentin
CC       filaments both in the central cytoplasm and at leading edges of
CC       migrating cells (PubMed:26578515, PubMed:26466680, PubMed:19846667).
CC       Colocalizes with F-actin, Arp2/3 complex and cortactin to leading edge
CC       lamellipodia, ruffles and macropinosomes of migrating cells
CC       (PubMed:26578515). {ECO:0000269|PubMed:19846667,
CC       ECO:0000269|PubMed:26466680, ECO:0000269|PubMed:26578515}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=CARMIL2a {ECO:0000303|PubMed:19846667};
CC         IsoId=Q6F5E8-1; Sequence=Displayed;
CC       Name=2; Synonyms=CARMIL2b {ECO:0000303|PubMed:19846667};
CC         IsoId=Q6F5E8-2; Sequence=VSP_047857, VSP_047858;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested, including thymus,
CC       spleen, colon, leukocytes, peripheral blood, skin, skin keratinocytes
CC       and skin fibroblasts. Strong expression is detected in naive and memory
CC       CD4+ and CD8+ T cells, naive and memory B cells, regulatory T cells and
CC       NK cells, whereas it is poorly expressed in monocytes
CC       (PubMed:27647349). {ECO:0000269|PubMed:15588584,
CC       ECO:0000269|PubMed:27647349}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal skin.
CC       {ECO:0000269|PubMed:15588584}.
CC   -!- DOMAIN: The N-terminal leucine-rich repeat (LRR) domain is necessary
CC       for localization to vimentin filaments (PubMed:26466680). The C-
CC       terminus is necessary for localization to the cell membrane
CC       (PubMed:26578515). {ECO:0000269|PubMed:26466680,
CC       ECO:0000269|PubMed:26578515}.
CC   -!- DISEASE: Immunodeficiency 58 (IMD58) [MIM:618131]: An autosomal
CC       recessive primary immunodeficiency characterized by a variety of
CC       infectious diseases, including mycobacterial diseases, mucocutaneous
CC       candidiasis, silent but detectable EBV viremia, and staphylococcal
CC       diseases. Patients suffer from dermatitis, esophagitis, recurrent skin
CC       abscesses and chest infections. Immunologic analysis shows defective T-
CC       cell function and deficient CD3/CD28 stimulation responses in both CD4+
CC       and CD8+ T cells. B-cell function may also be impaired.
CC       {ECO:0000269|PubMed:27647349, ECO:0000269|PubMed:27896283,
CC       ECO:0000269|PubMed:28112205, ECO:0000269|PubMed:29479355}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the CARMIL family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD26751.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB113647; BAD26751.1; ALT_INIT; mRNA.
DR   EMBL; FJ026014; ACI49710.1; -; mRNA.
DR   EMBL; AC009095; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010530; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS45513.1; -. [Q6F5E8-1]
DR   CCDS; CCDS81998.1; -. [Q6F5E8-2]
DR   RefSeq; NP_001013860.1; NM_001013838.1. [Q6F5E8-1]
DR   RefSeq; NP_001303955.1; NM_001317026.1. [Q6F5E8-2]
DR   AlphaFoldDB; Q6F5E8; -.
DR   SMR; Q6F5E8; -.
DR   BioGRID; 126970; 18.
DR   IntAct; Q6F5E8; 5.
DR   MINT; Q6F5E8; -.
DR   STRING; 9606.ENSP00000334958; -.
DR   GlyGen; Q6F5E8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q6F5E8; -.
DR   MetOSite; Q6F5E8; -.
DR   PhosphoSitePlus; Q6F5E8; -.
DR   BioMuta; CARMIL2; -.
DR   DMDM; 172045901; -.
DR   EPD; Q6F5E8; -.
DR   jPOST; Q6F5E8; -.
DR   MassIVE; Q6F5E8; -.
DR   MaxQB; Q6F5E8; -.
DR   PaxDb; Q6F5E8; -.
DR   PeptideAtlas; Q6F5E8; -.
DR   ProteomicsDB; 66290; -. [Q6F5E8-1]
DR   ProteomicsDB; 7286; -.
DR   Antibodypedia; 49241; 64 antibodies from 13 providers.
DR   DNASU; 146206; -.
DR   Ensembl; ENST00000334583.11; ENSP00000334958.5; ENSG00000159753.15. [Q6F5E8-1]
DR   Ensembl; ENST00000545661.5; ENSP00000441481.1; ENSG00000159753.15. [Q6F5E8-2]
DR   GeneID; 146206; -.
DR   KEGG; hsa:146206; -.
DR   MANE-Select; ENST00000334583.11; ENSP00000334958.5; NM_001013838.3; NP_001013860.1.
DR   UCSC; uc002etn.4; human. [Q6F5E8-1]
DR   AGR; HGNC:27089; -.
DR   CTD; 146206; -.
DR   DisGeNET; 146206; -.
DR   GeneCards; CARMIL2; -.
DR   HGNC; HGNC:27089; CARMIL2.
DR   HPA; ENSG00000159753; Tissue enhanced (brain, intestine, lymphoid tissue).
DR   MalaCards; CARMIL2; -.
DR   MIM; 610859; gene.
DR   MIM; 618131; phenotype.
DR   neXtProt; NX_Q6F5E8; -.
DR   OpenTargets; ENSG00000159753; -.
DR   Orphanet; 542301; Combined immunodeficiency due to CARMIL2 deficiency.
DR   PharmGKB; PA162401371; -.
DR   VEuPathDB; HostDB:ENSG00000159753; -.
DR   eggNOG; KOG4242; Eukaryota.
DR   GeneTree; ENSGT00940000161003; -.
DR   HOGENOM; CLU_003119_3_1_1; -.
DR   InParanoid; Q6F5E8; -.
DR   OMA; YIHNWRQ; -.
DR   OrthoDB; 5476233at2759; -.
DR   PhylomeDB; Q6F5E8; -.
DR   TreeFam; TF316381; -.
DR   PathwayCommons; Q6F5E8; -.
DR   SignaLink; Q6F5E8; -.
DR   BioGRID-ORCS; 146206; 10 hits in 1069 CRISPR screens.
DR   ChiTaRS; CARMIL2; human.
DR   GenomeRNAi; 146206; -.
DR   Pharos; Q6F5E8; Tbio.
DR   PRO; PR:Q6F5E8; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q6F5E8; protein.
DR   Bgee; ENSG00000159753; Expressed in right frontal lobe and 135 other tissues.
DR   ExpressionAtlas; Q6F5E8; baseline and differential.
DR   Genevisible; Q6F5E8; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0044354; C:macropinosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0051639; P:actin filament network formation; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; IDA:UniProtKB.
DR   GO; GO:0061339; P:establishment or maintenance of monopolar cell polarity; IDA:UniProtKB.
DR   GO; GO:2000813; P:negative regulation of barbed-end actin filament capping; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; IDA:UniProtKB.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; IDA:UniProtKB.
DR   GO; GO:1902745; P:positive regulation of lamellipodium organization; IDA:UniProtKB.
DR   GO; GO:1900029; P:positive regulation of ruffle assembly; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IBA:GO_Central.
DR   GO; GO:0034315; P:regulation of Arp2/3 complex-mediated actin nucleation; IBA:GO_Central.
DR   GO; GO:0044319; P:wound healing, spreading of cells; IDA:UniProtKB.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   InterPro; IPR031943; CARMIL_C.
DR   InterPro; IPR041245; CARMIL_PH.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   PANTHER; PTHR24112:SF32; CAPPING PROTEIN, ARP2/3 AND MYOSIN-I LINKER PROTEIN 2; 1.
DR   PANTHER; PTHR24112; LEUCINE-RICH REPEAT, ISOFORM F-RELATED; 1.
DR   Pfam; PF17888; Carm_PH; 1.
DR   Pfam; PF16000; CARMIL_C; 1.
DR   Pfam; PF13516; LRR_6; 2.
DR   SMART; SM00368; LRR_RI; 5.
DR   SUPFAM; SSF52047; RNI-like; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection; Cytoplasm;
KW   Cytoskeleton; Disease variant; Leucine-rich repeat; Membrane; Methylation;
KW   Phosphoprotein; Reference proteome; Repeat.
FT   CHAIN           1..1435
FT                   /note="Capping protein, Arp2/3 and myosin-I linker protein
FT                   2"
FT                   /id="PRO_0000325817"
FT   REPEAT          64..88
FT                   /note="LRR 1"
FT   REPEAT          89..111
FT                   /note="LRR 2"
FT   REPEAT          249..272
FT                   /note="LRR 3"
FT   REPEAT          274..297
FT                   /note="LRR 4"
FT   REPEAT          303..326
FT                   /note="LRR 5"
FT   REPEAT          335..362
FT                   /note="LRR 6"
FT   REPEAT          393..423
FT                   /note="LRR 7"
FT   REPEAT          429..452
FT                   /note="LRR 8"
FT   REPEAT          461..481
FT                   /note="LRR 9"
FT   REPEAT          492..514
FT                   /note="LRR 10"
FT   REPEAT          519..543
FT                   /note="LRR 11"
FT   REPEAT          546..572
FT                   /note="LRR 12"
FT   REPEAT          581..604
FT                   /note="LRR 13"
FT   REPEAT          608..631
FT                   /note="LRR 14"
FT   REPEAT          636..660
FT                   /note="LRR 15"
FT   REPEAT          664..687
FT                   /note="LRR 16"
FT   REGION          573..667
FT                   /note="Tropomodulin-like"
FT   REGION          965..1435
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1087..1114
FT                   /note="Necessary for localization at the cell membrane"
FT                   /evidence="ECO:0000269|PubMed:26578515"
FT   COMPBIAS        992..1006
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1020..1034
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1059..1079
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1187..1206
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1230..1249
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1257..1271
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1284..1302
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1407..1421
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         991
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         993
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1120
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3V3V9"
FT   MOD_RES         1246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1303
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3V3V9"
FT   MOD_RES         1315
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3V3V9"
FT   MOD_RES         1420
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3V3V9"
FT   VAR_SEQ         384..419
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:19846667"
FT                   /id="VSP_047857"
FT   VAR_SEQ         1346..1372
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:19846667"
FT                   /id="VSP_047858"
FT   VARIANT         50
FT                   /note="R -> T (in IMD58; decreased protein expression in
FT                   patient's cells; dbSNP:rs1567626023)"
FT                   /evidence="ECO:0000269|PubMed:29479355"
FT                   /id="VAR_081149"
FT   VARIANT         372
FT                   /note="L -> R (in IMD58; decreased protein expression in
FT                   patient's leukocytes; no effect on homodimerization;
FT                   dbSNP:rs1567628757)"
FT                   /evidence="ECO:0000269|PubMed:27647349"
FT                   /id="VAR_081150"
FT   VARIANT         525
FT                   /note="L -> Q (in IMD58; decreased protein expression in
FT                   patient's leukocytes; no effect on homodimerization;
FT                   dbSNP:rs1567629943)"
FT                   /evidence="ECO:0000269|PubMed:27647349"
FT                   /id="VAR_081151"
FT   VARIANT         639
FT                   /note="L -> H (in IMD58; dbSNP:rs775061512)"
FT                   /evidence="ECO:0000269|PubMed:27896283"
FT                   /id="VAR_081152"
FT   VARIANT         853..1435
FT                   /note="Missing (in IMD58; no detectable protein expression
FT                   in patient's leukocytes; no effect on homodimerization)"
FT                   /evidence="ECO:0000269|PubMed:27647349"
FT                   /id="VAR_081153"
FT   MUTAGEN         1021
FT                   /note="R->A: Loss of ability to bind heterodimeric capping
FT                   protein (CP), unable to inhibit the actin-capping activity
FT                   of CP and to rescue the loss of lamellipodial ruffling,
FT                   macropinocytosis, cell polarity, and invadopodia-mediated
FT                   matrix degradation; when associated with A-1023."
FT                   /evidence="ECO:0000269|PubMed:26466680"
FT   MUTAGEN         1023
FT                   /note="R->A: Loss of ability to bind heterodimeric capping
FT                   protein (CP), unable to inhibit the actin-capping activity
FT                   of CP and to rescue the loss of lamellipodial ruffling,
FT                   macropinocytosis, cell polarity, and invadopodia-mediated
FT                   matrix degradation; when associated with A-1021."
FT                   /evidence="ECO:0000269|PubMed:26466680"
FT   MUTAGEN         1096..1106
FT                   /note="KKLGTLFAFKK->EEEEEEEEEEE: Loss of accumulation at
FT                   the cell membrane. Does not alter colocalization at
FT                   vimentin filaments. Alters monopolar cell polarity,
FT                   increasing the number of leading edges lacking lamellipodia
FT                   and ruffles. Inhibits cell migration during wound healing."
FT                   /evidence="ECO:0000269|PubMed:26578515"
FT   MUTAGEN         1096..1106
FT                   /note="KKLGTLFAFKK->GGGGGGGGGGG: Loss of accumulation at
FT                   the cell membrane. Does not alter colocalization at
FT                   vimentin filaments. Alters monopolar cell polarity,
FT                   increasing the number of leading edges lacking lamellipodia
FT                   and ruffles. Inhibits cell migration during wound healing."
FT                   /evidence="ECO:0000269|PubMed:26578515"
FT   MUTAGEN         1096..1106
FT                   /note="Missing: Loss of accumulation at the cell membrane.
FT                   Does not alter colocalization at vimentin filaments. Alters
FT                   monopolar cell polarity, increasing the number of leading
FT                   edges lacking lamellipodia and ruffles. Inhibits cell
FT                   migration during wound healing."
FT                   /evidence="ECO:0000269|PubMed:26578515"
SQ   SEQUENCE   1435 AA;  154689 MW;  B0D452CE375436A5 CRC64;
     MAQTPDGISC ELRGEITRFL WPKEVELLLK TWLPGEGAVQ NHVLALLRWR AYLLHTTCLP
     LRVDCTFSYL EVQAMALQET PPQVTFELES LRELVLEFPG VAALEQLAQH VAAAIKKVFP
     RSTLGKLFRR PTPASMLARL ERSSPSESTD PCSPCGGFLE TYEALCDYNG FPFREEIQWD
     VDTIYHRQGC RHFSLGDFSH LGSRDLALSV AALSYNLWFR CLSCVDMKLS LEVSEQILHM
     MSQSSHLEEL VLETCSLRGD FVRRLAQALA GHSSSGLREL SLAGNLLDDR GMTALSRHLE
     RCPGALRRLS LAQTGLTPRG MRALGRALAT NAAFDSTLTH LDLSGNPGAL GASEDSGGLY
     SFLSRPNVLS FLNLAGTDTA LDTVRGCSVG GWMTGRADWR AGRGGLGPPA GVANSLPPQL
     FAAVSRGCCT SLTHLDASRN VFSRTKSRAA PAALQLFLSR ARTLRHLGLA GCKLPPDALR
     ALLDGLALNT HLRDLHLDLS ACELRSAGAQ VIQDLVCDAG AVSSLDLADN GFGSDMVTLV
     LAIGRSRSLR HVALGRNFNV RCKETLDDVL HRIVQLMQDD DCPLQSLSVA ESRLKLGASV
     LLRALATNPN LTALDISGNA MGDAGAKLLA KALRVNSRLR SVVWDRNHTS ALGLLDVAQA
     LEQNHSLKAM PLPLNDVAQA QRSRPELTAR AVHQIQACLL RNNRADPASS DHTTRLQPLG
     LVSDPSEQEV NELCQSVQEH VELLGCGAGP QGEAAVRQAE DAIQNANFSL SILPILYEAG
     SSPSHHWQLG QKLEGLLRQV GEVCRQDIQD FTQATLDTAR SLCPQMLQGS SWREQLEGVL
     AGSRGLPELL PEQLLQDAFT RLRDMRLSIT GTLAESIVAQ ALAGLSAARD QLVESLAQQA
     TVTMPPALPA PDGGEPSLLE PGELEGLFFP EEKEEEKEKD DSPPQKWPEL SHGLHLVPFI
     HSAAEEAEPE PELAAPGEDA EPQAGPSARG SPSPAAPGPP AGPLPRMDLP LAGQPLRHPT
     RARPRPRRQH HHRPPPGGPQ VPPALPQEGN GLSARVDEGV EEFFSKRLIQ QDRLWAPEED
     PATEGGATPV PRTLRKKLGT LFAFKKPRST RGPRTDLETS PGAAPRTRKT TFGDLLRPPT
     RPSRGEELGG AEGDTSSPDP AGRSRPRYTR DSKAYSMILL PAEEEATLGA RPDKRRPLER
     GETELAPSFE QRVQVMLQRI GVSRGSGGAE GKRKQSKDGE IKKAGSDGDI MDSSTEAPPI
     SIKSRTHSVS ADPSCRPGPG SQGPESATWK TLGQQLNAEL RSRGWGQQDG PGPPSPGQSP
     SPCRTSPSPD SLGLPEDPCL GPRNEDGQLR PRPLSAGRRA VSVHEDQLQA PAERPLRLQR
     SPVLKRRPKL EAPPSPSLGS GLGTEPLPPQ PTEPSSPERS PPSPATDQRG GGPNP
//
